According to DelveInsight’s analysis, the TROP2 ADC in the NSCLC market landscape is expected to evolve significantly, driven by new opportunities, following the approval of DATROWAY. Additionally, the expected launch of TROP2 ADCs in NSCLC, such as TRODELVY (sacituzumab govitecan)…
